Accretive Wealth Partners LLC Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Accretive Wealth Partners LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.7% during the third quarter, HoldingsChannel.com reports. The fund owned 6,045 shares of the company’s stock after selling 105 shares during the quarter. Accretive Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $720,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in NVO. Natixis Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares during the last quarter. Private Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after buying an additional 20,188 shares during the last quarter. Finally, Buckingham Capital Management Inc. bought a new stake in shares of Novo Nordisk A/S in the third quarter worth $3,874,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $102.77 on Friday. The company has a market capitalization of $461.18 billion, a P/E ratio of 33.26, a P/E/G ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm’s 50 day simple moving average is $116.12 and its two-hundred day simple moving average is $128.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analysts Set New Price Targets

A number of research analysts have weighed in on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.